 Biogen Inc NASDAQ: BIIB and Ionis Pharmaceuticals Inc NASDAQ: IONS have announced topline results from the Phase 1 study of BIIB078 IONIS-C9Rx for C9orf72-associated amyotrophic lateral sclerosis ALS. In this Phase 1 study, BIIB078 was generally well-tolerated. 